Zoran Veličković
Zoran is a Internal Medicine Resident at Institute of Rheumatology, School of Medicine, University of Belgrade, undertaking a PhD at the same institution. His work primarily focuses on investigating the adjunctive treatment for fibromyalgia such as transcranial magnetic stimulation and its influence on different outcomes, such as gait and balance. Zoran is a member of the Country Liaison Sub-committee
| Oral 0107 | Wednesday 12.06.24 17:40-17:50 PM Clinical Abstract Sessions: Risk factors and treatment in osteoporosis Author: Sebbag, E (France) Title: Nationwide epidemiology of fracture incidence in patients treated with denosumab: data on 271 295 patients from the French healthcare information system  This nationwide study demonstrates that cessation of Denosumab is associated with an increased fracture risks and that an immediate relay with bisphosphonate is often poorly executed, despite recommendations. |
| Poster Tour 0108 | Thursday 13.06.24 10:12-10:18 AM Clinical Poster Tours: Treatment Options in Metabolic bone diseases and Osteoporosis Author: Bousselham, S (Morocco) Title: Evaluation of oral bisphosphonate therapy compliance Compliance remains suboptimal, and greater attention should be paid to the therapeutic education of these patients being monitored for osteoporosis in order to optimise their management. |
| Oral Win| Thursday 13.06.24 10:30–11:15 AM What is new (WIN) Osteoarthritis and other mechanical musculoskeletal problems Author: Prof. Margreet Kloppenburg (Netherlands) Title: What is New: Hand osteoarthritis In this session, novel insights into the pathogenesis and treatment of hand osteoarthritis are presented. |
| Poster Tour 0319 | Friday 14.06.24 12:30-12:36 PM Clinical Poster Tours: Risk stratification in metabolic bone diseases Author: Martin, M (Italy) Title: Male osteoporosis and screening guidelines: an underestimated disease in aging population This study suggests that OP should be considered in all men when risk factors for low BMD and fractures are present, independently from age, being age sufficient for screening after 60 years of age. |
| Oral 0274 | Friday 14.06.24 11:10-11:20 AM Clinical Abstract Sessions: New developments in Osteoarthritis Author: Wang, W (China) Title: Placebo Response to Intra-articular Injections in Osteoarthritis Clinical Trials and Its Associated Factors This study developed a pharmacodynamic model that could quantitatively describe the placebo response of intra-articular injections for OA across various subpopulations and trial variables. |
| Oral 0326 | Friday 14.06.24 16:50–17:00 PM From Bench to Bedside Author: Yazici, Y (USA) Title: Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections over 3 Years in Subjects with Severe Knee Osteoarthritis Lorecivivint (LOR) continues to show promise as a safe, disease-modifying knee OA treatment. |